Amicus Therapeut Stock Price, News & Analysis

Amicus Therapeutics (Nasdaq: FOLD) will host a conference call and live audio webcast on November 5, 2020, at 8:30 a.m. ET to discuss its third-quarter financial results for the period ending September 30, 2020. Participants can join the call by dialing specific numbers and using the conference ID 7788189. A live audio webcast will also be available on the company's investor website. A replay of the call will be accessible for seven days post-event. Amicus Therapeutics focuses on developing innovative medicines for rare metabolic diseases.

Amicus Therapeutics (Nasdaq: FOLD) announced positive interim results from its AT-GTX-501 gene therapy program for CLN6 Batten disease. Data presented at the Child Neurology Congress indicates safety is well-maintained across 13 children, with efficacy shown in 12 patients at 12 months, and 8 at 24 months. The therapy slowed decline in motor and language function significantly compared to natural history cohorts. Regulatory discussions are ongoing, with the company expecting additional feedback in 2021.

Amicus Therapeutics (Nasdaq: FOLD) announced that the European Medicines Agency (EMA) granted Priority Medicines (PRIME) designation to AT-GTX-501, a gene therapy for children with variant late infantile neuronal ceroid lipofuscinosis 6 (CLN6 Batten disease). The PRIME designation aims to enhance support for development and expedite regulatory evaluations. This decision is based on Phase 1/2 clinical trial data, and additional results are expected at the Child Neurology Society Annual Meeting in October. In the U.S., AT-GTX-501 has already received Rare Pediatric Disease and Orphan Drug designations.

Amicus Therapeutics (Nasdaq: FOLD) announced its senior leadership team's participation in three virtual investor conferences in September 2020. Events include Citi's 15th Annual BioPharma Virtual Conference on September 10 at 8:55 a.m. E.T., Cantor Virtual Global Healthcare Conference on September 16 at 10:00 a.m. E.T., and Bank of America Global Healthcare Conference on September 18 at 4:45 p.m. B.S.T. Live audio webcasts can be accessed via the company's Investors section on their website.

Amicus focuses on developing innovative treatments for rare metabolic diseases.

Amicus Therapeutics (Nasdaq: FOLD) will host a conference call on August 10, 2020, at 8:30 a.m. ET to discuss its financial results for Q2 2020, which ended June 30, 2020. CEO John F. Crowley and the senior leadership team will lead the call. Investors can participate by dialing designated numbers or accessing it via a live audio webcast on the company's investor website. A replay will be available for seven days post-event. Amicus focuses on developing innovative medicines for rare metabolic diseases.

Amicus Therapeutics (FOLD) announced a $400 million credit facility with Hayfin Capital Management, paving a path to profitability without future dilutive financings. The financing aims to support the company's growth in rare diseases and retire a prior term loan. The facility features a 6.5% interest rate above LIBOR, requiring interest-only payments until mid-2024, and will be fully drawn at closing. Amicus expects Galafold revenues between $250 million and $260 million for 2020, emphasizing prudent expense management and a strong financial foundation.

Amicus Therapeutics (Nasdaq: FOLD) announces that CEO John F. Crowley will participate in a fireside chat at the Goldman Sachs 41^st Annual Global Healthcare Conference on June 10, 2020, at 8:00 a.m. ET. This event will take place virtually, allowing interested parties to access a live audio webcast via the company's Investor Relations page. Amicus Therapeutics focuses on developing innovative medicines for rare metabolic diseases, furthering its commitment to patients through a robust pipeline of advanced therapies. For details, visit www.amicusrx.com.

Amicus Therapeutics (Nasdaq: FOLD) announced the acceptance of multiple abstracts for the American Society of Gene & Cell Therapy 23rd Annual Meeting on May 12-15, 2020. The presentation includes preclinical data from the Pompe gene therapy program, alongside CLN6 and CLN8 Batten disease programs. The oral presentation is scheduled for May 14, showcasing a study on gene therapy for Pompe disease. Poster presentations will cover data on CLN6 and CLN8 Batten diseases. Pompe disease affects 5,000-10,000 people globally and is characterized by severe muscle weakness.

Amicus Therapeutics (Nasdaq: FOLD) announced acceptance of several abstracts for the American Society of Gene & Cell Therapy 23rd Annual Meeting held virtually from May 12-15, 2020. The highlights include:

• Oral Presentation: Preclinical data on Pompe gene therapy on May 14, 2020.
• Poster Presentations: Research on CLN6 Batten disease on May 12 and CLN8 Batten disease on May 13.

POMPE and Batten diseases are rare genetic disorders affecting muscle and neurological function, respectively.